Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line
- Company
- ASTRAZENECA PLC (AZN)
- Drug
- durvalumab
- Indication
- Hepatocellular Carcinoma
Other upcoming events for AZN
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
Phase 1 StartPhase 1 Start: A Phase I, Open-label Study to Assess the Absorption, Distribution, Metabolism, and Excretion (ADME)
Phase 1 StartPhase 1 Start: A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerabi
Phase 2 StartPhase 2 Start: A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Sa
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.